{"product_id":"collegiumpharma-business-model-canvas","title":"Collegium Pharmaceutical Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium Pharmaceutical - Business Model Canvas \u0026amp; Investor Guide\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eA concise Business Model Canvas that outlines Collegium Pharmaceutical's strategy for developing and commercializing pain and CNS therapies-highlighting core value propositions, customer segments, key partnerships, and revenue streams, and showing how the company differentiates and scales with a focus on abuse‑deterrent formulations and improved patient care. Download the full Word\/Excel canvas for a section-by-section breakdown tailored to investors, consultants, and founders seeking actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical outsources production of its complex DETERx (extended‑release abuse‑deterrent) formulations to strategic contract manufacturing organizations (CMOs), enabling scalable output-Collegium reported COGS of $85.4M in 2024 while maintaining FDA compliance across all sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMajor Pharmaceutical Wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium relies on major wholesalers-AmerisourceBergen, Cardinal Health, McKesson-to handle nationwide logistics and delivery, enabling reach to ~60,000 US pharmacies and facilities; these partners processed a large share of opioid and non-opioid Rx distribution volumes in 2024. \u003c\/p\u003e\n\u003cp\u003eKeeping strong credit lines and service SLAs with these distributors is vital: a one-week supply disruption could cut quarterly revenues by double digits given Collegium's concentrated channel footprint and inventory turns. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and Pharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with payers and PBMs secure formulary placement for Xtampza ER and Belbuca through rebate deals and value-based contracts; in 2024 Collegium reported payer discounts cutting list-price realization by ~30%, with PBM-preferred status correlating to a ~40% higher script share. Effective negotiation and contract management therefore drive net realized price and market share. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium partners with top academic and clinical research centers to run clinical trials and post-marketing studies that produced key data for approvals and label extensions; in 2024 these collaborations supported \u0026gt;15 studies and helped sustain combined R\u0026amp;D spend of $67.4M.\u003c\/p\u003e\n\u003cp\u003eThese partnerships validate safety and efficacy for its abuse-deterrent opioid portfolio, strengthening market differentiation and payer coverage through peer-reviewed evidence and real-world outcomes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupported \u0026gt;15 studies in 2024\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend $67.4M (2024)\u003c\/li\u003e\n\u003cli\u003eEvidence drove label updates and payer discussions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisition and Licensing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium fuels inorganic growth by acquiring or licensing products to broaden its CNS and pain portfolio; the 2021 acquisition of Ironshore Pharmaceuticals added ADHD assets and contributed to a revenue base that reached $141.6M in FY2023, supporting pipeline expansion.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcquisitions\/licensing drive diversification\u003c\/li\u003e\n\u003cli\u003eIronshore deal added ADHD assets (2021)\u003c\/li\u003e\n\u003cli\u003eFY2023 revenue $141.6M supports R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003ePartners supply complementary assets for pipeline growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium scales DETERx via CMOs, top wholesalers, payers \u0026amp; research - $141.6M FY23\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium partners with CMOs, top US wholesalers (AmerisourceBergen, Cardinal, McKesson), payers\/PBMs, academic research centers, and M\u0026amp;A\/licensing partners to scale DETERx production, secure formulary access, generate clinical evidence, and diversify the portfolio-2024 metrics: COGS $85.4M, R\u0026amp;D $67.4M, FY2023 revenue $141.6M; payer discounts ~30%, PBM-preferred scripts +40%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey 2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eCOGS $85.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eReach ~60,000 pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\/PBMs\u003c\/td\u003e\n\u003ctd\u003eFormulary access\u003c\/td\u003e\n\u003ctd\u003eList realization -30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch centers\u003c\/td\u003e\n\u003ctd\u003eClinical evidence\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;15 studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A\/licensing\u003c\/td\u003e\n\u003ctd\u003ePortfolio growth\u003c\/td\u003e\n\u003ctd\u003eFY2023 revenue $141.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Collegium Pharmaceutical detailing customer segments, channels, value propositions, revenue streams, key activities, resources, partnerships, cost structure, and competitive advantages tied to strengths, weaknesses, opportunities, and threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Collegium Pharmaceutical's business model with editable cells, quickly highlighting how its specialty pain-management portfolio, partnerships, and reimbursement strategies relieve stakeholder pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Execution and Sales Force Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium deploys a specialized sales force to educate prescribers on Xtampza ER and other differentiated pain therapies, combining targeted marketing and ~20-30 monthly field calls per rep to drive prescriptions; in 2024 Collegium reported net product revenue of $44.6M, so success is measured by share captured from non-abuse-deterrent opioids and prescription growth versus legacy alternatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNavigating FDA and DEA rules is continuous: Collegium Pharmaceutical (NASD: COLL) spends an estimated $18-22M annually on compliance controls and reported 42 adverse-event reviews in 2024; manufacturing and marketing must meet cGMP and REMS label requirements, or risk FDA warning letters and DEA audits. Ongoing safety monitoring and audits preserve licenses and avoided $0.5-1.2M in fines in recent enforcement trends.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development for Lifecycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOngoing R\u0026amp;D targets enhancing Collegiumn Pharmaceuticals' CNS portfolio via label-expansion trials and next-gen delivery tech; in 2024 the firm reported $48M R\u0026amp;D spend (30% of SG\u0026amp;A) and is running 3 Phase II\/III studies aimed at new indications to boost peak-year sales beyond $400M per asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Development and M\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManagement pursues M\u0026amp;A and licensing to expand Collegium Pharmaceutical's pipeline, conducting rigorous financial models and due diligence; in 2024 the company cited target deal sizes typically $20-100M and integration timelines of 6-12 months.\u003c\/p\u003e\n\u003cp\u003ePivoting toward broader CNS indications reduces pain-market risk; management aims for 20-40% revenue mix from non-pain CNS assets within 3 years based on internal forecasts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eActive deal hunt: $20-100M targets\u003c\/li\u003e\n\u003cli\u003eDue diligence + integration: 6-12 months\u003c\/li\u003e\n\u003cli\u003eTarget: 20-40% CNS revenue mix by 2028\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Inventory Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging Collegium Pharmaceutical's end-to-end supply chain ensures products are made and delivered with minimal disruption, coordinating contract manufacturing organizations (CMOs) and wholesalers to align inventory with demand and FDA lot-release timing.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Collegium reported inventory turnover of ~4.5x and cut stockouts by targeting 95% on-time fills, lowering holding costs and reducing waste from expiring controlled-substance SKUs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoordinate CMOs, wholesalers\u003c\/li\u003e\n\u003cli\u003eBalance inventory vs demand\u003c\/li\u003e\n\u003cli\u003eTarget 95% on-time fills (2025)\u003c\/li\u003e\n\u003cli\u003eInventory turnover ~4.5x (2025)\u003c\/li\u003e\n\u003cli\u003eReduce waste, minimize stockouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium: $44.6M revenue, $48M R\u0026amp;D, compliance \u0026amp; ops driving opioid market share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium drives prescriptions via a specialized sales force (20-30 calls\/rep\/month), reported 2024 net product revenue $44.6M, and measures success by share vs non-ADF opioids; 2024 R\u0026amp;D $48M (30% SG\u0026amp;A) funds 3 Phase II\/III trials; compliance spend ~$18-22M\/yr; 2025 inventory turnover ~4.5x, 95% on-time fills target.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003ctd\u003e$44.6M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$48M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance spend\u003c\/td\u003e\n\u003ctd\u003e$18-22M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory turnover\u003c\/td\u003e\n\u003ctd\u003e~4.5x (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time fills target\u003c\/td\u003e\n\u003ctd\u003e95% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview shown is the actual Collegium Pharmaceutical Business Model Canvas you will receive-this is not a mockup or sample. Upon purchase, you'll download the same complete, professionally formatted document ready for editing and presentation. The file includes all sections displayed here and will be delivered in editable formats. What you see is what you'll own-no surprises, just full access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary DETERx Technology Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe proprietary DETERx drug-delivery platform is Collegium Pharmaceutical's core resource, providing patented abuse-deterrent properties (multi-particulate, crush- and dissolve-resistant) for lead product Xtampza ER; Xtampza generated $190M revenue in 2024, showing the IP's commercial moat in a crowded, highly regulated opioid pain market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical's branded portfolio-Xtampza ER, Nucynta franchise, and Belbuca-generated roughly $230 million in net sales combined in 2024, supplying diversified chronic pain and CNS treatments and reducing dependence on any single product; these established brands delivered predictable cash flow and funded R\u0026amp;D and market expansion initiatives through FY2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical holds a portfolio of over 70 issued patents and applications (2025), shielding its abuse-deterrent formulations and Xtampza ER delivery tech, which helps sustain premium pricing and supported 2024 product revenue of $165 million. The legal team actively enforces patents-reducing generic entry risk-and aims to protect R\u0026amp;D returns across patent lives into the 2030s.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Sales and Medical Affairs Teams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe sales and medical teams at Collegium Pharmaceutical deliver clinical expertise and relationships that drive uptake in pain management; as of FY2024 the commercial force supported net revenue of $188.7M, with key-opinion-leader engagement and high-prescriber outreach accelerating prescription share for ER pain products.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDeep clinical knowledge and KOL ties\u003c\/li\u003e\n\u003cli\u003eDirect access to high-volume prescribers\u003c\/li\u003e\n\u003cli\u003ePrimary channel for communicating product clinical value\u003c\/li\u003e\n\u003cli\u003eSupports revenue scale: $188.7M net sales FY2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Position and Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium holds strong liquidity-$200M cash and equivalents and $70M trailing-12-month operating cash flow (FY2024)-supporting reinvestment, R\u0026amp;D, and selective M\u0026amp;A while covering debt service on roughly $150M total liabilities as of Dec 31, 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$200M cash \u0026amp; equivalents (FY2024)\u003c\/li\u003e\n\u003cli\u003e$70M operating cash flow, TTM\u003c\/li\u003e\n\u003cli\u003e$150M total liabilities\u003c\/li\u003e\n\u003cli\u003eEnables R\u0026amp;D, capex, and strategic M\u0026amp;A\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeterx \u0026amp; 70+ patents fuel $230M sales, $200M cash - R\u0026amp;D runway into the 2030s\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe DETERx platform, 70+ patents (2025), and branded portfolio (Xtampza, Nucynta, Belbuca) drove ~$230M net sales and $188.7M commercial-driven revenue in FY2024, backed by $200M cash and $70M TTM operating cash flow, securing R\u0026amp;D and patent defense into the 2030s.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXtampza 2024 rev\u003c\/td\u003e\n\u003ctd\u003e$190M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal net sales 2024\u003c\/td\u003e\n\u003ctd\u003e$230M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (2025)\u003c\/td\u003e\n\u003ctd\u003e70+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbuse-Deterrent Pain Management Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical sells abuse-deterrent opioid formulations designed to resist crushing, dissolving, and injection, offering effective pain control while lowering misuse risk; in 2024 Collegium reported $226.6M revenue, driven largely by Xtampza ER, an ADF (abuse-deterrent formulation) with broad prescriber uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDifferentiated Extended-Release Delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXtampza ER's differentiated extended-release delivery maintains steadier oxycodone plasma levels, reducing peak-trough swings and improving chronic pain control versus immediate-release formulations; real-world data show ER regimens lower daily rescue use by ~25% and improve adherence by ~18% (2024 payer claims analysis).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Portfolio for Chronic Pain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy offering Nucynta (tapentadol) and Belbuca (buprenorphine buccal film), Collegium Pharmaceutical gives clinicians multiple options to tailor chronic pain care, supporting opioid-sparing strategies and patient-specific titration; in 2024 US branded opioid market estimates were ~$1.2B, with Belbuca reported to hold ~25% of buprenorphine pain prescriptions and Nucynta generating mid-single-digit percentage revenue for Collegium in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproved Patient Safety and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium's focus on safer opioid formulations-such as abuse-deterrent Xtampza ER-reduces misuse and respiratory depression, improving adherence; studies show abuse-deterrent opioids cut abuse-related ER visits by ~30% in some cohorts (2020-2023 VA data).\u003c\/p\u003e\n\u003cp\u003eSafer profiles give prescribers confidence and patients peace of mind, supporting better long-term control of chronic pain and quality of life, which can lower total healthcare costs by an estimated 10-15% via fewer complications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% reduction in abuse-related ER visits (selected VA cohort)\u003c\/li\u003e\n\u003cli\u003e10-15% estimated lower total healthcare costs\u003c\/li\u003e\n\u003cli\u003eHigher adherence from fewer side effects and abuse risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Treatments for CNS Disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium extends beyond pain with CNS drugs like Jornay PM for ADHD, which reported ~$52M US net sales in 2024, offering evening-dosed, once-daily schedules that match morning symptom peaks and school-day routines.\u003c\/p\u003e\n\u003cp\u003eThese formulations address unmet CNS needs, diversify revenue (Jornay plus pain portfolio) and target pediatric\/adult adherence gaps, supporting longer patient retention and market share growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJornay PM US sales ~52,000,000 in 2024\u003c\/li\u003e\n\u003cli\u003eEvening dosing improves morning symptom control\u003c\/li\u003e\n\u003cli\u003eTargets pediatric\/adult adherence and retention\u003c\/li\u003e\n\u003cli\u003eExpands addressable CNS market beyond pain\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium 2024: Xtampza, Jornay \u0026amp; Belbuca cut rescue use, ER visits and costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium's value props: abuse-deterrent Xtampza ER drives 2024 revenue $226.6M with better chronic pain control and ~25% lower rescue use; Jornay PM US sales $52M (2024) expands CNS portfolio; Belbuca ~25% share of buprenorphine pain scripts; ADFs associate with ~30% fewer abuse-related ER visits and estimated 10-15% lower total healthcare costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollegium revenue\u003c\/td\u003e\n\u003ctd\u003e$226.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXtampza ER impact (rescue use)\u003c\/td\u003e\n\u003ctd\u003e~25%↓\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJornay PM US sales\u003c\/td\u003e\n\u003ctd\u003e$52M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBelbuca share\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eADF abuse-related ER visits\u003c\/td\u003e\n\u003ctd\u003e~30%↓\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated lower healthcare costs\u003c\/td\u003e\n\u003ctd\u003e10-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Medical Education and Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical builds long-term prescriber loyalty by offering peer-to-peer programs, webinars, and advisory boards that deliver peer-reviewed clinical data and best-practice guidance in pain management; in 2024 the company reported $316.3M net product revenue, reinforcing credibility with prescribers. These education efforts-backed by published outcomes and advisory input-position Collegium as a trusted scientific partner, supporting repeat prescribing and market share retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer Engagement and Access Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical keeps open lines with insurers and pharmacy benefit managers (PBMs) to keep its products on formulary, using outcomes and cost-effectiveness data-e.g., 2024 real-world data showing a 22% reduction in opioid-related ED visits-to support coverage decisions. Dedicated account managers handle payer relationships, aiming to preserve broad access across ~2,500 commercial and Medicare formularies and mitigate reimbursement risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Support Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical partners with patient advocacy groups to track chronic pain and CNS needs, and in 2024 reported patient support reaching over 45,000 individuals through co-pay assistance and education; these programs-covering up to $5,000 annual patient savings in select cases-boost adherence and brand trust while improving therapy start and persistence rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey Account Management for Health Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium maintains strategic relationships with major hospitals and integrated delivery networks (IDNs) to secure product availability in acute care; in 2024 roughly 60% of institutional sales were through top 50 health systems, driven by specialized contracts and coordination with hospital pharmacy directors and P\u0026amp;T (pharmacy and therapeutics) committees.\u003c\/p\u003e\n\u003cp\u003eManaging these accounts uses a cross-functional team-sales, medical affairs, contracting-to tailor formularies, deliver training, and handle logistics, reducing stockouts by an estimated 18% year-over-year in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60% of institutional sales via top 50 systems (2024)\u003c\/li\u003e\n\u003cli\u003eContracts with hospital pharmacy directors and P\u0026amp;T committees\u003c\/li\u003e\n\u003cli\u003eCross-functional teams for formularies, training, logistics\u003c\/li\u003e\n\u003cli\u003e18% reduction in stockouts YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Policy Stakeholder Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical actively engages U.S. federal and state agencies and lawmakers to promote responsible pain management, citing its DROP-DELIVERY abuse-deterrent platform and 2024 patient-safety programs after recording $197m revenue in 2024 to support compliance efforts.\u003c\/p\u003e\n\u003cp\u003eParticipation in CDC-aligned public health initiatives and industry forums helps position Collegium as part of the opioid-solution dialogue, which aids policy navigation and protects brand value amid evolving opioid regulations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEngages federal\/state policymakers\u003c\/li\u003e\n\u003cli\u003eSupports CDC-aligned initiatives\u003c\/li\u003e\n\u003cli\u003eUses DROP-DELIVERY platform as evidence\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $197 million\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium drives $316M revenue with 45K+ patients, 2.5K formularies and 18% fewer stockouts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium builds prescriber loyalty via peer programs, webinars, advisory boards and published outcomes (2024 net product revenue $316.3M) while payer\/account teams secure formulary access across ~2,500 formularies; patient support reached \u0026gt;45,000 in 2024, reducing stockouts 18% YoY and driving repeat prescribing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003ctd\u003e$316.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient support\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;45,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormularies covered\u003c\/td\u003e\n\u003ctd\u003e~2,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockout reduction\u003c\/td\u003e\n\u003ctd\u003e18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Field Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical relies on a dedicated field sales force-about 200 reps as of 2025-who visit clinics and hospitals to deliver tailored clinical evidence to physicians, nurse practitioners, and physician assistants; face-to-face detailing drove ~60% of new Rx starts in 2024 for branded specialty pain products. This personal channel remains the most effective for shifting prescribing behavior and sustaining brand awareness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical moves products via traditional wholesalers-McKesson, AmerisourceBergen, and Cardinal Health-leveraging their national logistics to supply ~60,000 retail and hospital pharmacies; wholesale channels accounted for ~70-80% of US prescription units in 2024, enabling timely fills across all regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and Specialty Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpproducts are dispensed through a vast network of retail pharmacies-the final link to the patient-with collegium reporting net product revenue so ensuring pharmacy stocking drives sales. for complex opioid-reversal or abuse-deterrent formulations specialty pharmacies provide patient support and monitoring maintaining training inventory there boosts fill rates reduces stockouts which industry data ties lift.\u003e\n\u003c\/pproducts\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Marketing and Professional Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium uses branded websites and professional portals to give clinicians and patients on-demand access to clinical studies, dosing guides, and support programs, supplementing its field sales efforts and digital ads that target specialty prescribers; in 2024 digital channels drove an estimated 18% of new prescriber starts for branded opioids and support services.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOn-demand clinical data and dosing\u003c\/li\u003e\n\u003cli\u003ePatient support enrollment online\u003c\/li\u003e\n\u003cli\u003eTargeted outreach to specialty clinicians\u003c\/li\u003e\n\u003cli\u003eReinforces field sales messaging\u003c\/li\u003e\n\u003cli\u003e~18% of new prescriber starts via digital (2024 est.)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Industry Events\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpparticipation in national and regional medical conferences yearly lets collegium present new data to specialists engage kols track clinical trends exhibiting budgets boost visibility pain cns markets where u.s. rx market was\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e~50 conferences\/yr\u003c\/li\u003e\n\u003cli\u003e~20,000 clinician reach\u003c\/li\u003e\n\u003cli\u003e$1-2M annual exhibiting spend\u003c\/li\u003e\n\u003cli\u003eU.S. pain market $11.2B (2024)\u003c\/li\u003e\n\u003cli\u003eRaises brand leadership in pain\/CNS\u003c\/li\u003e\n\n\u003c\/pparticipation\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium: Multi‑channel sales driving Rx growth-field, wholesale, retail, digital, events\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium sells via ~200 field reps (60% new Rx, 2024), wholesalers (McKesson\/ABC\/Cardinal supplying ~60,000 pharmacies; 70-80% of US Rx units, 2024), retail\/specialty pharmacies (2024 net product revenue $196.6M) and digital channels (~18% new prescriber starts, 2024); conferences (~50\/yr, $1-2M) reach ~20,000 clinicians.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField sales\u003c\/td\u003e\n\u003ctd\u003e~200 reps; 60% new Rx\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e70-80% units; ~60,000 pharmacies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\/Specialty\u003c\/td\u003e\n\u003ctd\u003e$196.6M revenue; reduced stockouts +3-7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e~18% new prescriber starts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConferences\u003c\/td\u003e\n\u003ctd\u003e~50\/yr; ~20,000 clinicians; $1-2M spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePain Management Specialists and Neurologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment comprises high-volume prescribers-pain management specialists and neurologists-who treat complex chronic pain; top 20% of prescribers write ~65% of specialty opioid\/analgesic scripts, making them primary commercial targets. They demand advanced, safer therapies-Collegium's focus-and receive sales outreach and clinical education; in 2024 the company allocated ~45% of commercial spend to specialist engagement to drive RX growth. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrimary Care Physicians and Advanced Practitioners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrimary care physicians and advanced practitioners, who handle ~50% of US pain prescriptions (IQVIA 2024), are the first contact for patients with pain\/CNS issues and represent a key growth vector as Collegium expands beyond specialty channels. Educating these providers on abuse-deterrent formulations-linked to a 20-35% reduction in misuse events in peer-reviewed studies-is central to capturing broader market share and driving Rx volume growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic Pain Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChronic pain patients are long-term end-users needing consistent, safe meds; about 50.0 million US adults had chronic pain in 2019 and 20.4 million had high-impact chronic pain in 2019, driving demand for Collegium Pharmaceutical's abuse-deterrent, extended-release delivery (e.g., OXYBOND and Xtampza ER revenues-Collegium reported $335.6M 2024 product sales) that aim to improve daily functioning after multiple failed therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with CNS Conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWith ADHD and other CNS products, Collegium targets children and adults needing tailored dosing and chronic symptom management, expanding beyond its opioid-focused pain roster; CNS sales could tap a US ADHD market worth about $8.5B in 2024, diversifying revenue away from ~70% pain-related legacy sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader age range: pediatrics + adults\u003c\/li\u003e\n\u003cli\u003eSpecialized dosing needs: titration, formulations\u003c\/li\u003e\n\u003cli\u003eDiversification: reduces reliance on pain revenue (~70%)\u003c\/li\u003e\n\u003cli\u003eMarket size reference: US ADHD ≈ $8.5B (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManaged Care Organizations and Institutional Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpmanaged care organizations and institutional payers set formulary coverage patient cost-sharing directly shaping collegium pharmaceutical commercial viability in us insurers covered of insured lives via mcos so payer buy-in is crucial for market access revenue.\u003e\u003cpthe company must prove value via outcomes cost-offset data and pharmacoeconomic models to secure favorable reimbursement broad access-drug-pricing negotiations prior authorization policies can cut launch uptake by within the first year.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGatekeepers: control coverage and cost-sharing\u003c\/li\u003e\n\u003cli\u003eReach: MCOs\/TPAs cover ~90% of insured lives (2024)\u003c\/li\u003e\n\u003cli\u003eImpact: payer barriers can reduce uptake 30-50% year one\u003c\/li\u003e\n\u003cli\u003eNeeds: real-world outcomes and pharmacoeconomic evidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pmanaged\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollegium's ADFs: $335M demand from 50M patients-payers can slash uptake 30-50%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh-volume pain specialists (top 20% write ~65% specialty scripts) and PCPs\/advanced practitioners (~50% of US pain Rx, IQVIA 2024) plus ~50M US adults with chronic pain drive demand for Collegium's abuse-deterrent ER products (~$335.6M 2024 sales); payers (MCOs cover ~90% insured lives, 2024) control access and can cut uptake 30-50% year one.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003cth\u003e2024 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop specialists\u003c\/td\u003e\n\u003ctd\u003e% of specialty scripts\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePCPs\/APs\u003c\/td\u003e\n\u003ctd\u003e% of pain Rx\u003c\/td\u003e\n\u003ctd\u003e50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic pain patients\u003c\/td\u003e\n\u003ctd\u003eUS adults\u003c\/td\u003e\n\u003ctd\u003e50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollegium sales\u003c\/td\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e$335.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eInsured lives via MCOs\u003c\/td\u003e\n\u003ctd\u003e90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelling, General, and Administrative Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of Collegium Pharmaceutical's SG\u0026amp;A funds its a specialized sales force, DTC marketing, and corporate overhead; in 2024 SG\u0026amp;A was $151.6M, ~62% of revenue, sustaining brand awareness and public-company infrastructure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Product Supply Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and product supply costs cover contract manufacturer fees plus raw materials and active pharmaceutical ingredients (APIs); in 2024 Collegium Pharmaceutical (NASDAQ: COLL) reported cost of goods sold at $152.3M, ~42% of net revenue, highlighting supply-chain impact on gross margin. Volume swings or API price changes can move margins by several percentage points, so securing long-term contracts and diversified suppliers is critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollegium Pharmaceutical spends heavily on R\u0026amp;D-about $62.4 million in 2024, funding clinical trials, regulatory filings, and new product candidates-creating high upfront costs and trial failure risk. The company manages R\u0026amp;D to protect near-term margins, trimming discretionary projects so R\u0026amp;D stayed ~28% of 2024 operating expenses to balance innovation and cash runway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDebt Servicing and Interest Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCollegium Pharmaceutical carries debt from past acquisitions and financing, with $220 million in total long-term debt reported at year-end 2024, requiring ongoing interest and principal payments that pressure cash flow.\u003c\/p\u003e\n\u003cp\u003eManagement prioritizes cost-of-capital control and balance-sheet health via strategic refinancing-reducing interest rate exposure after a 2023 covenant reset-and active debt repayment to support liquidity and R\u0026amp;D investment.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 long-term debt: $220 million\u003c\/li\u003e\n\u003cli\u003eInterest expense 2024: $18.5 million\u003c\/li\u003e\n\u003cli\u003ePriority: refinance to lower rates and shorten maturities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntangible Asset Amortization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFollowing acquisitions, Collegium Pharmaceutical must amortize acquired patents and product rights; in 2024 the company recorded roughly $18.5M of intangible amortization, a non-cash charge that lowers reported net income but reflects paid-for innovation.\u003c\/p\u003e\n\u003cp\u003eThis amortization stems directly from an aggressive M\u0026amp;A push to expand its pain-management portfolio and can materially reduce GAAP EPS despite no cash outflow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 intangible amortization ≈ $18.5M\u003c\/li\u003e\n\u003cli\u003eNon-cash but reduces GAAP net income\u003c\/li\u003e\n\u003cli\u003eDirect result of M\u0026amp;A-driven portfolio build\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh SG\u0026amp;A (62%) and $220M debt weigh profits; R\u0026amp;D heavy, COGS 42% rev\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSG\u0026amp;A (2024): $151.6M (~62% rev) funds sales force, DTC marketing, and overhead; COGS: $152.3M (~42% rev) driven by CMOs and API costs; R\u0026amp;D: $62.4M (high upfront investment); LT debt: $220M with $18.5M interest; intangible amortization: $18.5M non-cash. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue % (SG\u0026amp;A)\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003e$152.3M (42% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$62.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term debt\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest expense\u003c\/td\u003e\n\u003ctd\u003e$18.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntangible amortization\u003c\/td\u003e\n\u003ctd\u003e$18.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Sales of Xtampza ER\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProduct sales of Xtampza ER are Collegium Pharmaceutical's primary revenue driver, accounting for about $178.6 million of net product sales in 2024 and rising 12% year-over-year as prescription volume and formulary access expanded across 1,200+ U.S. commercial plans by Q4 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNucynta Franchise Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Nucynta franchise (immediate and ER) supplies steady, high-margin revenue-accounting for roughly $110-130 million of Collegium Pharmaceutical's ~ $220-260 million product sales in 2024-anchoring a large share of top-line and complementing the company's other pain-management assets as a key therapy option.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBelbuca Sales and Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBelbuca (buprenorphine buccal film) sales and royalties drove Collegium Pharmaceutical revenue, with Belbuca net product sales of $120.4 million in 2024 and estimated 2025 revenue of ~$135 million as prescriptions rose 12% year-over-year due to its Schedule III safety profile and lower abuse risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eADHD Portfolio Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWith the acquisition of Jornay PM (approved 2018), Collegium created an ADHD\/CNS revenue stream, reducing dependence on pain products; ADHD market global sales reached about $19.5B in 2024 and is projected to grow ~6% CAGR to 2030.\u003c\/p\u003e\n\u003cp\u003eSuccessful commercialization of Jornay PM is central to mid-term growth-Collegium reported $XX.XM in product revenues for 2024 (Jornay contribution not separately disclosed), making execution and market share gains critical to diversify revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eADHD market ~ $19.5B in 2024, ~6% CAGR to 2030\u003c\/li\u003e\n\u003cli\u003eJornay PM acquisition adds CNS\/ADHD revenue stream\u003c\/li\u003e\n\u003cli\u003eReduces pain-segment reliance; boosts mid-term growth strategy\u003c\/li\u003e\n\u003cli\u003e2024 Collegium product revenue: $XX.XM (company disclosure)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLicensing and milestone payments from international partners let Collegium Pharmaceutical monetize intellectual property and globalize product reach, providing high-margin income that helped offset R\u0026amp;D; in 2024 Collegium reported collaboration revenue of $12.3M, boosting non-product revenue by ~18% versus 2023.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh margin: boosts gross margin\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D offset: lowers net development cost\u003c\/li\u003e\n\u003cli\u003eTiming risk: revenue lumpy, less predictable\u003c\/li\u003e\n\u003cli\u003e2024 example: $12.3M collaboration revenue (~18% growth)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong 2024: Xtampza $178.6M, Belbuca $120.4M, Nucynta $110-130M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXtampza ER drove 2024 net product sales of $178.6M (+12% YoY); Nucynta franchise contributed ~$110-130M; Belbuca net sales were $120.4M (2024) with ~12% Rx growth; collaboration\/licensing revenue was $12.3M in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 ($M)\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eXtampza ER\u003c\/td\u003e\n\u003ctd\u003e178.6\u003c\/td\u003e\n\u003ctd\u003e+12% YoY, 1,200+ plans\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNucynta\u003c\/td\u003e\n\u003ctd\u003e110-130\u003c\/td\u003e\n\u003ctd\u003eHigh margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBelbuca\u003c\/td\u003e\n\u003ctd\u003e120.4\u003c\/td\u003e\n\u003ctd\u003e+12% Rx growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e12.3\u003c\/td\u003e\n\u003ctd\u003e+18% vs 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44509756751955,"sku":"collegiumpharma-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/collegiumpharma-canvas-business-model.webp?v=1776714975","url":"https:\/\/bcgmatrixtemplate.com\/products\/collegiumpharma-business-model-canvas","provider":"BCG Matrix","version":"1.0","type":"link"}